5th International Conference on
Cancer Research and Treatment

This session highlights recent advances in systemic cancer treatments, including novel chemotherapy protocols and combination regimens. It will feature insights into overcoming multidrug resistance and enhancing treatment efficacy with targeted delivery technologies.

Experts will present breakthroughs in nanocarrier systems, liposomal formulations, and localised intratumoral therapies. Emphasis will be placed on reducing toxicity and improving patient tolerability while maximising therapeutic outcomes. Case studies and clinical trial updates will support evidence-based discussions.

Subtracks:

• Advances in Chemotherapy Regimens
• Nanoparticle and Liposome-Based Delivery
• Overcoming Multidrug Resistance
• Pharmacokinetics & Pharmacodynamics in Oncology
• Intratumoral Drug Delivery Techniques
• Chemotherapy-Induced Toxicity Management

Dedicated to the dynamic field of cancer immunotherapy, this session will explore immune checkpoint blockade, cellular therapies, and tumour microenvironment modulation. Experts will address the latest mechanisms of immune escape and resistance, along with biomarkers for therapy response prediction.

The session will spotlight novel combination strategies aimed at enhancing anti-tumour immunity and patient survival outcomes. Presentations will include updates on clinical trials, translational research, and regulatory perspectives. Interactive discussions will focus on challenges in integrating immunotherapy into clinical practice.

Subtracks:

• Immune Checkpoint Blockade
• Tumour-Infiltrating Lymphocyte Therapy
• CAR-T and CAR-NK Therapies
• Immunotherapy Combination Strategies
• Immune-Related Adverse Events Management
•  Cancer Vaccine Development

This session provides a focused exploration of advancements in breast cancer screening, diagnostics, and targeted therapies. It will discuss molecular classification, genetic risk assessment, and subtype-specific treatment protocols. Special attention will be given to innovations in imaging, reconstructive surgery, and novel systemic treatments like CDK4/6 inhibitors. Experts will examine patient-centred approaches, survivorship care, and quality of life considerations. Recent clinical trial outcomes and evolving global trends will also be reviewed.

Subtracks:

• Triple-Negative Breast Cancer Advances
• HER2-Targeted Therapies
• Breast Imaging Innovations
• Genetic Risk Assessment & BRCA Mutation Studies
• Breast-Conserving and Reconstructive Surgery
• Survivorship and Quality of Life

This session delves into the complexities of diagnosing and managing central nervous system (CNS) tumours. Discussions will cover advancements in imaging modalities, surgical innovations, and molecular classification of primary and metastatic brain tumours.

Experts will address unique challenges in treating high-grade gliomas, paediatric brain tumours, and CNS metastases. The role of immunotherapy and novel drug delivery systems in overcoming the blood-brain barrier will be explored. Multidisciplinary care models and clinical trial data will inform evidence-based practice discussions.

Subtracks:

• Glioma Biology and Treatment
• Innovations in Neuroimaging
• Blood-Brain Barrier Disruption Techniques
• Paediatric Brain Tumour Management
• CNS Metastasis Therapeutics
• Neuro-Oncology Surgery

This session highlights the essential role of radiology in cancer detection, staging, treatment planning, and response assessment. Experts will present advances in imaging technologies, including AI-enhanced radiomics, theranostics, and molecular imaging.

Discussions will focus on improving diagnostic accuracy, reducing invasive procedures, and integrating imaging biomarkers into personalised oncology care. Emerging trends in image-guided interventions and AI-powered predictive analytics will be explored. The session aims to redefine imaging as a therapeutic tool alongside its diagnostic function.

Subtracks:

• PET, MRI, and CT in Oncology
• AI-Driven Cancer Imaging
• Theranostics and Radiopharmaceuticals
• Radiomics and Imaging Biomarkers
• Image-Guided Tumour Ablation
• Molecular Imaging in Cancer Detection

This session offers an in-depth examination of modern surgical techniques in cancer treatment, focusing on minimally invasive, robotic-assisted, and reconstructive surgeries. Experts will discuss perioperative management, tumour staging, and strategies for improving oncological and functional outcomes.

Subtracks:

• Robotic and Minimally Invasive Cancer Surgery
• Sentinel Node Maapping and Tumour Staging
• Oncoplastic and Reconstructive Techniques
• Surgery in Rare and Complex Tumours
• Multidisciplinary Surgical Planning
• Postoperative Recovery and Quality of Life

Emphasis will be placed on multidisciplinary tumour boards and integrating surgery with chemotherapy and radiotherapy. Innovations in tumour localisation, intraoperative imaging, and postoperative recovery protocols will also be covered. Case-based discussions will illustrate evidence-based surgical decision-making.

Focusing on cutting-edge genetic and cellular approaches, this session will explore gene editing, adoptive cell transfer, and stem cell-based cancer therapies. Experts will discuss the application of CRISPR-Cas9, viral vectors, and non-viral systems for tumour-specific gene modifications.

Clinical updates on CAR-T and CAR-NK therapies will be presented, along with strategies to overcome immune evasion and tumour heterogeneity. Ethical and regulatory frameworks for gene and cell therapies will also be addressed. Real-world patient experiences and trial data will underpin discussions.

Subtracks:

• CRISPR, TALEN, and Gene Editing in Oncology
• Viral and Non-Viral Gene Delivery Systems
• CAR-T and CAR-NK Cell Therapy Advances
• Stem Cell-Based Therapeutics
• Regulatory and Ethical Considerations
• Overcoming Immune Escape in Solid Tumours

This session explores immunotherapy innovations and therapeutic cancer vaccines as transformative strategies in oncology. Topics will include checkpoint inhibitors, adoptive T-cell therapies, tumour-specific vaccines, and immune modulators.

Experts will examine mechanisms of immune resistance and biomarker-driven personalisation of immunotherapies. Combination strategies to enhance efficacy and overcome limitations of monotherapies will be highlighted.

Subtracks:

• Checkpoint Inhibitor Therapy Developments
• Therapeutic Cancer Vaccines
• Biomarkers for Immunotherapy Response
• Combination Immunotherapy Strategies
• Immune Escape and Resistance Mechanisms
• T-cell Based Adoptive Immunotherapies

This session focuses on the clinical management and molecular underpinnings of haematologic malignancies including leukaemia, lymphoma, and multiple myeloma. Discussions will cover diagnostic innovations, risk stratification, and evolving therapeutic strategies, such as targeted agents and immunotherapies.

Case studies will illustrate management of minimal residual disease and treatment-resistant cases. Stem cell transplantation and cellular therapies will be explored as curative options in specific settings. The session will review recent guidelines and clinical trial outcomes.

Subtracks:

• Acute and Chronic Leukaemia Management
• Lymphoma Therapeutic Strategies
• Multiple Myeloma Updates
• Minimal Residual Disease Monitoring
• Cellular Therapies in Haematologic Cancers
• Stem Cell Transplantation Innovations

This session examines the complex biological mechanisms driving cancer metastasis, from tumour cell invasion to colonisation of distant organs. Discussions will focus on epithelial-mesenchymal transition (EMT), angiogenesis, and interactions within the tumour microenvironment that facilitate metastasis.

Experts will present new insights into circulating tumour cells (CTCs) and exosome-mediated signalling. Innovative therapeutic targets aimed at halting metastasis progression will also be explored. Attendees will gain a deeper understanding of why metastasis remains the leading cause of cancer mortality.

Subtracks:

• Epithelial-Mesenchymal Transition and Metastasis
• Circulating Tumour Cells and Liquid Biopsy
• Tumour Angiogenesis in Metastatic Spread
• Organ-Specific Metastatic Mechanisms
• Exosomes and Metastatic Niche Formation
• Anti-Metastatic Drug Targets

This session highlights precision oncology’s growing role through targeted therapies that address specific genetic mutations and cellular pathways. Experts will discuss the latest approved targeted agents and ongoing clinical trials investigating kinase inhibitors, PARP inhibitors, and angiogenesis blockers.

Emphasis will be placed on resistance mechanisms and strategies to overcome them using combination therapies. Molecular diagnostics and companion testing will also be featured. Attendees will discover how these therapies are reshaping cancer care paradigms.

Subtracks:

• Tyrosine Kinase Inhibitors in Solid and Haematologic Tumours
• PARP Inhibitors in BRCA-Associated Cancers
• Anti-Angiogenic Therapy
• Mechanisms of Drug Resistance and Overcoming Strategies
• Companion Diagnostics in Targeted Therapy
• Emerging Targets in Rare and Aggressive Cancers

A visionary session spotlighting pioneering research directions and transformative breakthroughs in oncology. Experts will present studies on tumour genomics, novel biomarkers, and therapeutic resistance pathways.

Discussions will also cover liquid biopsies, organoid models, and tumour heterogeneity. The future of precision oncology, AI-driven analytics, and integrative medicine will be explored. This session aims to inspire collaborations that bridge basic research and clinical application.

Subtracks:

• Liquid Biopsy and Circulating Biomarkers
• Tumour Organoids and Preclinical Models
• Novel Therapeutic Resistance Pathways
• AI and Bioinformatics in Oncology Research
• Cancer Epigenetics and Non-Coding RNAs
• Emerging Molecular Targets

This session covers the diagnosis and management of haematologic malignancies and disorders affecting the lymphatic system. Topics will include bleeding and clotting disorders in cancer patients, lymphomas, and rare haematologic neoplasms.

Discussions will explore advances in molecular diagnostics, immunotherapy, and transplant techniques. The session also addresses lymphoedema management and lymphatic metastasis. Case-based learning will reinforce evidence-based care pathways.

Subtracks:

• Lymphoma Biology and Therapeutics
• Coagulopathies in Oncology Patients
• Haematopoietic Stem Cell Transplantation
• Minimal Residual Disease in Blood Cancers
• Immunotherapy in Haematologic Malignancies
• Lymphoedema and Lymphatic Metastasis

This session focuses on the pharmacological basis of cancer therapy, including mechanisms of drug action, pharmacokinetics, and toxicity profiles. Experts will discuss drug resistance, combination regimens, and pharmacogenomics in oncology. Emerging agents like antibody-drug conjugates (ADCs) and targeted kinase inhibitors will be featured. Case discussions will highlight the optimisation of dosing and therapeutic drug monitoring to improve clinical outcomes.

Subtracks:

• Mechanisms of Action of Cancer Therapeutics
• Pharmacogenomics in Oncology Drug Selection
• Drug-Drug Interactions and Toxicity Management
• Antibody-Drug Conjugates and Biologic Therapies
• Therapeutic Drug Monitoring in Oncology

A forward-looking session addressing the integration of artificial intelligence, machine learning, and digital health technologies in oncology. Topics include AI-powered imaging, predictive analytics, digital pathology, and patient monitoring platforms.

Experts will discuss ethical, regulatory, and data privacy concerns while highlighting real-world applications of digital tools in diagnosis, treatment, and clinical decision-making. This session aims to demystify AI and prepare oncologists for the future of data-driven cancer care.

Subtracks:

• AI in Diagnostic Radiology and Pathology
• Predictive Analytics for Patient Outcomes
• Digital Twins and Virtual Patient Simulations
• Wearable and Remote Monitoring in Cancer Care
• Ethical AI Implementation in Oncology
• AI in Clinical Trial Design and Recruitment

Dedicated to addressing the unique biological, clinical, and psychosocial aspects of paediatric and rare cancers. This session will discuss molecular subtypes, genetic syndromes, and treatment-related challenges specific to these patient populations.

Emphasis will be placed on long-term survivorship, fertility preservation, and late effects of therapy. Experts will also explore research networks and collaborative initiatives essential for advancing care in these often-overlooked areas.

Subtracks:

• Molecular Drivers in Paediatric Tumours
• Rare Adult Cancers: Diagnosis and Management
• Long-Term Survivorship and Late Effects
• Fertility Preservation in Young Cancer Patients
• Rare Tumour Registries and Research Networks
• Paediatric CAR-T and Immunotherapy

This session focuses on improving quality of life for cancer patients through comprehensive symptom management, psychosocial support, and integrative care models. Experts will present approaches for addressing emotional, spiritual, and family needs during the cancer journey. Palliative care integration into active treatment plans and survivorship care will also be explored.

Subtracks:

• Pain and Symptom Management in Cancer
• Psychosocial Oncology and Patient Counselling
• Nutritional and Supportive Interventions
• End-of-Life Care and Decision-Making
• Integrative and Complementary Therapies
• Palliative Care in Paediatric and Geriatric Oncology

This session highlights recent discoveries in cancer genomics, from driver mutations to tumour mutational burden and neoantigen prediction. Experts will discuss multi-omics approaches, epigenomics, and liquid biopsy applications. The session aims to translate genetic discoveries into actionable therapeutic strategies and personalised treatment plans. It will also explore the future of precision oncology driven by real-time genomic data.

Subtracks:

• Tumour Genomic Profiling and Biomarker Discovery
• Multi-Omics Approaches in Cancer Research
• Liquid Biopsy for Real-Time Tumour Monitoring
• Neoantigen Prediction for Personalised Immunotherapy
• Cancer Epigenomics and Methylation Markers
• AI in Genomic Data Interpretation

An essential session exploring the design, conduct, and analysis of oncology clinical trials. Discussions will address challenges in trial recruitment, adaptive trial designs, and real-world data integration.

Experts will share updates on pivotal oncology trials and regulatory landscapes. Emphasis will be placed on patient safety, ethical considerations, and strategies to improve diversity in trial participation.

Subtracks:

• Adaptive and Basket Trial Designs
• Real-World Data in Oncology Research
• Ethical and Regulatory Aspects of Trials
• Patient-Reported Outcomes in Clinical Trials
• Challenges in Rare Cancer Trials
• Digital Tools for Trial Management and Recruitment

• Oncology Drug Discovery & Development
• Preventive Oncology and Risk Reduction
• Nutrition, Lifestyle & Cancer Care
• Global Perspectives in Oncology
• Next-Generation Oncology: Future Trends & Technologies
• Nervous System Tumours and Management
• Reproductive System Cancers
• Digestive System Malignancies
• Respiratory System Oncology
• Urinary System Tumours
• Musculoskeletal Cancers
• Prostate & Genitourinary Cancers
• Skin and Melanoma Research
• Endocrine Tumours & Thyroid Oncology